Exane BNP Paribas analyst Lucas Herrmann downgrades Chevron (NYSE:CVX) from Neutral to Underperform.
Regulus Therapeutics Q3 EPS $(0.50) Misses $(0.49) Estimate
Regulus Therapeutics (NASDAQ:RGLS) reported quarterly losses of $(0.50) per share which missed the analyst consensus estimate of $(0.49) by 2.04 percent. This is a 50 percent increase over losses of $(1.00) per share